TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bacterial envelope with ICD replacements
News | 03. 24. 2010
TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce infection, announced today that it has begun enrollment in CITADEL, the second of two large scale, prospective, multicenter studies.